Insights

A medical expert discusses current and prospective treatment strategies for RSV.

Eliot Brinton, MD, highlights disease burden and treatment considerations for patients with homozygous familial hypercholesterolemia (HoFH).

David Lieberman, MD, PhD, provides an overview of Rett Syndrome, explores the patient perspective of Rett Syndrome, and discusses methods clinicians and payers use to evaluate treatment successes.

Two experts discuss the burden of disease, the treatment landscape, and the urgency to treat lupus nephritis.

A panel of experts discuss the treatment landscape of upper GI cancer, as well as unmet needs in GI, gastric, gastroesophageal junction, and esophageal cancers.

Three experts discuss HIV management with PrEP therapies, highlighting the major obstacles that can impact these patients and what can be done to improve their quality of life.

Three experts discuss the use of biosimilar and interchangeable biosimilars, exploring how the treatment landscape will change in the upcoming years.

A panel of expert medical professionals navigate the evolving landscape in biomarker testing for treating patients with metastatic colorectal cancer.

Three experts discuss advanced non-small cell lung cancer and what it means to have a treat a KRAS G12C mutation.

Two experts, one provider and one payer, shed light on their experiences with prescription digital therapeutics within the behavioral care landscape.

Two experts discuss the role immunomodulatory drugs (IMiDs) play in the current treatment landscape for relapsed/refractory multiple myeloma and how they can be used effectively.

Ian Riddock, MD, and Eliot Brinton, MD, discuss effective use of lipid lowering therapies in patients with atherosclerotic cardiovascular disease (ASCVD).

Shared insight on the role cardiovascular disease management plays in the prostate cancer treatment paradigm.

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.

X. Long Zheng, MD, PhD, gives an overview of acquired thrombotic thrombocytopenic purpura and the treatment considerations for the disease.

Rheumatologist Ellen Ginzler, MD, MPH, and nephrologist German Hernandez, MD, FASN, FACP, explore the current treatment landscape of lupus nephritis and the managed care considerations of recent FDA approved therapies for the disease.

Key opinion leaders discuss the key differences and unmet needs in disease management for heart failure with preserved ejection fraction and heart failure with reduction ejection fraction.

Oncologists explore the opportunity of CAR T-cell therapy for the treatment of relapsed/refractory multiple myeloma.

A clinician and payer discuss the impact of chemotherapy-induced neutropenia on patients as well as the healthcare system, and discuss the latest in prophylactic treatment, especially during the COVID-19 pandemic.

Examining current treatment options for brain metastases in metastatic HER2+ breast cancer and assessing the clinical and economic burden.

The impact of the COVID-19 pandemic on managing HIV and strategies implemented to address challenges faced by providers.